跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 130 条关于
“glomerulopathy”
全部
130
临床试验
55
药物
0
机构
0
资讯
75
去年
Novartis' Fabhalta Demonstrates Sustained Benefits in Phase III Trial for C3 Glomerulopathy
去年
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy
去年
Novartis' Fabhalta Shows Sustained Efficacy in C3 Glomerulopathy at 12 Months
去年
Fabhalta Demonstrates Sustained Efficacy in C3 Glomerulopathy Patients at 12 Months
去年
Error parsing response
去年
Pegcetacoplan Shows Promise in C3 Glomerulopathy and IC-MPGN: VALIANT Trial Results
7个月前
Novartis Reports Positive Phase III Results for Fabhalta in Rare Kidney Disease C3 Glomerulopathy
3天前
One04 Therapeutics Launches on Encouraging CPV-104 Phase 1 Interim Data in C3 Glomerulopathy
去年
FDA Grants Rare Pediatric Disease Designation to Omeros' Zaltenibart for C3 Glomerulopathy
去年
Eleva Advances Factor H Therapy CPV-104 into First-in-Human Trial for Rare Kidney Disease C3 Glomerulopathy
第 1 页,共 8 页
上一页
下一页